In the third quarter, Lee Financial Co initiated a new position in UnitedHealth Group by acquiring 3,390 shares valued at approximately $1.17 million, according to its latest Form 13F filing with the SEC. Several other institutional investors also expanded their holdings: Brighton Jones LLC raised its ownership by 176.2% to 44,249 shares (worth about $22.38 million), Revolve Wealth Partners LLC increased its position by 137.1% to 4,019 shares (approximately $2.03 million), Patriot Financial Group Insurance Agency LLC boosted its stake by 42.5% to 5,312 shares (about $1.66 million), and Montz Harcus Wealth Management LLC added 74 shares, growing its holding by 12.2% to 679 shares (around $212,000). CMT Capital Markets Trading GmbH also entered with a new stake valued near $340,000. Collectively, hedge funds and institutional investors now control 87.86% of UnitedHealth’s outstanding shares.

Wall Street research reports have been mixed in recent weeks. Jefferies Financial Group lowered its target from $418 to $340 while maintaining a Buy rating, citing valuation concerns. TD Cowen modestly raised its target from $335 to $338 but retained a Hold view, pointing to margin pressures. Oppenheimer trimmed its objective from $415 to $385 yet reaffirmed an Outperform stance based on long-term fundamentals. Zacks Research upgraded shares from Strong Sell to Hold following the company’s updated guidance, and KeyCorp reaffirmed an Overweight recommendation. Of the 29 analysts covering UnitedHealth, one rates it Strong Buy, seventeen rate it Buy, nine rate it Hold and two rate it Sell, producing an average consensus of Moderate Buy.

For the quarter ended December 31, UnitedHealth reported adjusted earnings per share of $2.11, beating consensus by $0.02. Revenue reached $113.22 billion but fell short of the forecast by $160 million, reflecting a 12.3% year-over-year increase. Net margin stood at 2.69% and return on equity was 14.79%. Compared with Q4 of the prior year—which featured a $6.81 per-share contribution from a one-time gain—core earnings growth was constrained by higher medical costs and subdued price realization in certain benefit lines.

UnitedHealth issued full-year 2026 guidance of $17.75 or more in EPS, below the Street estimate of roughly $29.50 due to anticipated headwinds in its benefits business. Management expects revenue of at least $439 billion, implying a modest decline from 2025 levels. The board declared a quarterly dividend of $2.21 per share, yielding approximately 3.1% on an annualized basis, with a payout ratio near 67%. As of January 27, the company’s debt-to-equity ratio was 0.72, current ratio 0.79 and quick ratio 0.82, reflecting a conservative leverage profile and stable liquidity position.